Norgine in $342 million deal to buy Merus

11 May 2017
mergers-acquisitions-big

Independent drugmaker Norgine is to acquire specialty pharma company Merus Labs International (Nasdaq: MSLI) in a $342 million deal, news of which sent the latter company’s share price spiraling by 54% to $1.19 in Thursday morning’s trading.

Norgine, a leading European specialist pharmaceutical company focusing on gastroenterology, hepatology, cancer and supportive care, had total sales of 295 million euros ($321 million) in 2016, almost three times Merus’ gross basic revenue for the year, which was $111 million.

"Our acquisition of Merus will strengthen our position as the ‘go-to’ European specialist pharma"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical